GlassScriptPhysician profile
Michael J Lopez
NPI 1437744976
$3,142.61
in general payments reported to CMS, 2019-2025
13 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $1,281 · 2023: $1,112 · 2024: $260 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,522.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,082.21 | 2021-2024 | |
| Viiv Healthcare Company | $538.59 | 2021-2024 | Dovato, Cabenuva |
| Janssen Biotech, INC. | $260.50 | 2021-2023 | Prezcobix |
| Abbvie INC. | $259.39 | 2021-2023 | |
| Theratechnologies INC. | $234.88 | 2022-2024 | Egrifta, Trogarzo |
| Janssen Products, LP | $221.33 | 2022-2023 | Symtuza |
| Alkermes, INC. | $190.38 | 2023-2024 | Vivitrol, Vivitrol |
| Merck Sharp & Dohme LLC | $127.10 | 2021-2024 | Pifeltro, Delstrigo |
| Astrazeneca Pharmaceuticals LP | $126.10 | 2021-2025 | Airsupra |
| Pfizer INC. | $37.26 | 2024 | |
| Exact Sciences Corporation | $24.87 | 2025 | Cologuard Collection Kit |
| Indivior INC. | $23.53 | 2025 | Sublocade |
| Prescient Lab Services, LLC | $16.47 | 2025 | Avertd Amplification Mix, Avertd Biofilmchip Microarray Magazine, Avertd Intellipac Reagent Module |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.